TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02473315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
Study: NCT00185692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
Study: NCT02439892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and nutrition during radiotherapy
Description: The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
Study: NCT00989781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will undergo 3 oral glcuose tolerance tests.
Study: NCT02439892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidimensional rehabilitation after radiotherapy
Description: The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
Study: NCT03009318

Intervention type: OTHER
Group type: OTHER
Intervention: tumors are confirmed by surgery and pathology
Description: Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
Study: NCT00603018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
Study: NCT01532869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously weekly, Weeks 0-48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Weeks 0-48
Study: NCT00459043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474
Description: Taken orally once every morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given on the first day of every treatment cycle (every 3 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given on the first day of every treatment cycle (every 3 weeks)
Study: NCT02982837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN & Nucleos(t)tide analogues
Description: Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)tide analogues
Description: Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)tide analogues
Description: Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
Study: NCT01532869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Week 48-96

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously weekly, Week 48-96
Study: NCT03322670

Intervention type: OTHER
Intervention: Signs of CAP and a positive chest X-Ray
Description: * collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28

Intervention type: OTHER
Intervention: Patients directly hospitalized
Description: * collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90

Intervention type: DIAGNOSTIC_TEST
Intervention: Control patients
Description: - bacteriological examinations (urine)

Intervention type: OTHER
Intervention: Patients with partial participation
Description: - collection of clinical examination data

Intervention type: OTHER
Intervention: Signs of CAP and a negative chest X-Ray
Description: * collection of clinical examination data~* telephone contact on day 28
Study: NCT04314076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic auditory stimulation
Description: RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.

Intervention type: OTHER
Group type: OTHER
Intervention: Gait Training
Description: Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
Study: NCT00521222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone with salmeterol
Description: Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone with salmeterol
Description: Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone HFA
Description: Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone HFA
Description: Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups
Study: NCT02473315

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cryotherapy
Description: The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
Study: NCT00006478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT04419038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with topical application of Mitomycin C
Description: Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with topical application of Mitomycin C
Description: Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with Ologen implantation
Description: Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autografting augmented with Ologen implantation
Description: Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
Study: NCT01328756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
Study: NCT04127747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of rituximab
Description: Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized dose of rituximab
Description: Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
Study: NCT02333565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study: NCT03471117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg daily for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills for 1 month
Study: NCT03571906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele - Cardiac Pre-Rehabilitation
Description: We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
Study: NCT03442998

Intervention type: OTHER
Group type: OTHER
Intervention: Suburban walk
Description: Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).

Intervention type: OTHER
Group type: OTHER
Intervention: Nature walk
Description: Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
Study: NCT00521222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium HFA
Description: Primary as-needed rescue medication in all treatment groups
Study: NCT01688388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
Study: NCT03999294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMGIM Music Therapy Method
Description: The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
Study: NCT02009332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered after ABI-009 in the Phase 2 study.
Study: NCT02070276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-thoracic echocardiography
Description: Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising Test
Description: Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
Study: NCT02936609

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study: NCT01390753

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human donor milk
Study: NCT02912338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistant Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study: NCT01505309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft (Medtronic, Microport, Ankura)
Description: Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
Study: NCT01280721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
Study: NCT02411175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homeopathic Remedy
Description: 20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
Study: NCT00521222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups
Study: NCT04654260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy for Irritability in Autism
Description: The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Description: Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
Study: NCT00556413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT02446964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study: NCT04295317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody SHR-1210
Description: PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
Study: NCT01986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.